Dr. Pranav Loyalka, MD
Claim this profileHCA Houston Healthcare Medical Center
Affiliated Hospitals
HCA Houston Healthcare Medical Center
Park Plaza Hospital
Clinical Trials Pranav Loyalka, MD is currently running
AccuCinch System
for Heart Failure
This trial is testing a new device called the AccuCinch Ventricular Restoration System in patients with a specific type of heart failure. The device helps the heart pump blood more effectively by supporting and reshaping its lower chamber. The study aims to see if this device, combined with standard medical treatment, is safe and effective. The CorCap Cardiac Support Device (CSD) is a predecessor that has shown safety and effectiveness in improving left ventricular structure and function in heart failure patients.
Recruiting
1 award
N/A
9 criteria
PCI vs Medical Management
for Aortic Stenosis
Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty about the benefits and the optimal timing of revascularization for such patients. There is currently clinical equipoise regarding the management of concomitant CAD in patients undergoing TAVR. Some centers perform routine revascularization with percutaneous coronary intervention (PCI) (either before or after TAVR), while others follow an alternative strategy of medical management. The potential benefits and optimal timing of PCI in these patients are unknown. As TAVR expands to lower risk patients, and potentially becomes the preferred therapy for the majority of patients with severe aortic stenosis, the optimal management of concomitant coronary artery disease will be of increasing importance. The COMPLETE TAVR study will determine whether, on a background of guideline-directed medical therapy, a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the composite outcome of Cardiovascular Death, new Myocardial Infarction, Ischemia-driven Revascularization or Hospitalization for Unstable Angina or Heart Failure. The study will be a randomized, multicenter, open-label trial with blinded adjudication of outcomes. Patients will be screened and consented for elective transfemoral TAVR and randomized within 96 hours of successful balloon expandable TAVR. Complete Revascularization: Staged PCI using third generation drug eluting stents to treat all suitable coronary artery lesions in vessels that are at least 2.5 mm in diameter and that are amenable to treatment with PCI and have a ≥70% visual angiographic diameter stenosis. Staged PCI can occur any time from 1 to 45 days post successful transfemoral TAVR. Vs. Medical Therapy Alone: No further revascularization of coronary artery lesions. All patients, regardless of randomized treatment allocation, will receive guideline-directed medical therapy consisting of risk factor modification and use of evidence-based therapies. The COMPLETE TAVR study will help address the current lack of evidence in this area. It will likely impact both the global delivery of health care and the management and clinical outcomes of all patients undergoing TAVR with concomitant CAD.
Recruiting
1 award
N/A
4 criteria
More about Pranav Loyalka, MD
Clinical Trial Related
8 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Pranav Loyalka, MD has experience with
- Edwards PASCAL System
- Optimal Medical Therapy
- TriClip Device
- Evolut™ PRO And Evolut™ PRO+ System
- Evolut™ FX System
- MitraClip™ Device Implantation
Breakdown of trials Pranav Loyalka, MD has run
Heart Failure
Tricuspid Valve Regurgitation
Tricuspid Regurgitation
Stroke
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Pranav Loyalka, MD specialize in?
Pranav Loyalka, MD focuses on Heart Failure and Tricuspid Valve Regurgitation. In particular, much of their work with Heart Failure has involved treating patients, or patients who are undergoing treatment.
Is Pranav Loyalka, MD currently recruiting for clinical trials?
Yes, Pranav Loyalka, MD is currently recruiting for 5 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Pranav Loyalka, MD has studied deeply?
Yes, Pranav Loyalka, MD has studied treatments such as Edwards PASCAL System, Optimal Medical Therapy, TriClip device.
What is the best way to schedule an appointment with Pranav Loyalka, MD?
Apply for one of the trials that Pranav Loyalka, MD is conducting.
What is the office address of Pranav Loyalka, MD?
The office of Pranav Loyalka, MD is located at: HCA Houston Healthcare Medical Center, Houston, Texas 77004 United States. This is the address for their practice at the HCA Houston Healthcare Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.